These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37658561)

  • 1.
    Paschali A
    Hell J Nucl Med; 2023; 26 Suppl():38-41. PubMed ID: 37658561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The "Undetermined Significance" of
    Treglia G; Bertagna F; Albano D
    Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441062
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Whole-body (18)F-FDG PET identifies high-risk myeloma.
    Durie BG; Waxman AD; D'Agnolo A; Williams CM
    J Nucl Med; 2002 Nov; 43(11):1457-63. PubMed ID: 12411548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bone marrow abnormalities and early bone lesions in multiple myeloma and its precursor disease: a prospective study using functional and morphologic imaging.
    Bhutani M; Turkbey B; Tan E; Korde N; Kwok M; Manasanch EE; Tageja N; Mailankody S; Roschewski M; Mulquin M; Carpenter A; Lamping E; Minter AR; Weiss BM; Mena E; Lindenberg L; Calvo KR; Maric I; Usmani SZ; Choyke PL; Kurdziel K; Landgren O
    Leuk Lymphoma; 2016 May; 57(5):1114-21. PubMed ID: 26690712
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The value of fluorodeoxyglucose positron emission tomography in multiple myeloma].
    Adam Z; Bolcák K; Stanícek J; Pour L; Hájek R; Krejcí M; Prásek J; Neubauer J; Mareschova Y; Vorlícek J
    Vnitr Lek; 2006 Mar; 52(3):207-14. PubMed ID: 16722151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of FDG PET in the staging of multiple myeloma.
    Vicentini JRT; Bredella MA
    Skeletal Radiol; 2022 Jan; 51(1):31-41. PubMed ID: 33813607
    [No Abstract]   [Full Text] [Related]  

  • 7. Diagnostic relevance of 18F-FDG PET/CT in newly diagnosed patients with monoclonal gammopathy of undetermined significance (MGUS): Single-center experience.
    Sandecka V; Adam Z; Krejci M; Stork M; Rehak Z; Koukalova R; Sevcikova S; Brozova L; Kral Z; Mayer J; Pour L
    Neoplasma; 2020 Jul; 67(4):939-945. PubMed ID: 32567936
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic relevance of 2-[
    Rudolphi-Solero T; Triviño-Ibáñez EM; González-Jiménez AD; Ramos-Font C; Ríos-Tamayo R; Rebollo-Aguirre AC; Sánchez-Sánchez R
    Hematol Oncol; 2023 Aug; 41(3):434-441. PubMed ID: 36222822
    [TBL] [Abstract][Full Text] [Related]  

  • 9. State-of-the-Art Imaging and Staging of Plasma Cell Dyscrasias.
    Amini B; Yellapragada S; Shah S; Rohren E; Vikram R
    Radiol Clin North Am; 2016 May; 54(3):581-96. PubMed ID: 27153790
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [18F-FDG PET/CT and 99mTc-MIBI scintigraphy in evaluation of patients with multiple myeloma and monoclonal gammopathy of unknown significance: comparison of methods].
    Myslivecek M; Bacovský J; Scudla V; Koranda P; Minarík J; Buriánková E; Formánek R; Zapletalová J
    Klin Onkol; 2010; 23(5):325-31. PubMed ID: 21061682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. 11C-acetate PET/CT for metabolic characterization of multiple myeloma: a comparative study with 18F-FDG PET/CT.
    Ho CL; Chen S; Leung YL; Cheng T; Wong KN; Cheung SK; Liang R; Chim CS
    J Nucl Med; 2014 May; 55(5):749-52. PubMed ID: 24676754
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ¹⁸F-FDG PET/CT: a review of diagnostic and prognostic features in multiple myeloma and related disorders.
    Dammacco F; Rubini G; Ferrari C; Vacca A; Racanelli V
    Clin Exp Med; 2015 Feb; 15(1):1-18. PubMed ID: 25218739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of
    Cavo M; Terpos E; Nanni C; Moreau P; Lentzsch S; Zweegman S; Hillengass J; Engelhardt M; Usmani SZ; Vesole DH; San-Miguel J; Kumar SK; Richardson PG; Mikhael JR; da Costa FL; Dimopoulos MA; Zingaretti C; Abildgaard N; Goldschmidt H; Orlowski RZ; Chng WJ; Einsele H; Lonial S; Barlogie B; Anderson KC; Rajkumar SV; Durie BGM; Zamagni E
    Lancet Oncol; 2017 Apr; 18(4):e206-e217. PubMed ID: 28368259
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
    Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of (11)C-4'-thiothymidine, (11)C-methionine, and (18)F-FDG PET/CT for the detection of active lesions of multiple myeloma.
    Okasaki M; Kubota K; Minamimoto R; Miyata Y; Morooka M; Ito K; Ishiwata K; Toyohara J; Inoue T; Hirai R; Hagiwara S; Miwa A
    Ann Nucl Med; 2015 Apr; 29(3):224-32. PubMed ID: 25421383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. (18)F-FDG dynamic PET/CT in patients with multiple myeloma: patterns of tracer uptake and correlation with bone marrow plasma cell infiltration rate.
    Sachpekidis C; Mai EK; Goldschmidt H; Hillengass J; Hose D; Pan L; Haberkorn U; Dimitrakopoulou-Strauss A
    Clin Nucl Med; 2015 Jun; 40(6):e300-7. PubMed ID: 25783508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of 18-FDG PET/CT and whole-body diffusion-weighted MRI in the assessment of multiple myeloma.
    Mesguich C; Hulin C; Latrabe V; Lascaux A; Bordenave L; Hindié E; Marit G
    Ann Hematol; 2020 Dec; 99(12):2869-2880. PubMed ID: 32951093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of MRI and computed tomography in the various stages of plasma cell disorders: correlations with biological and histological findings. Myélome-Midi-Pyrénées Group.
    Laroche M; Assoun J; Sixou L; Attal M
    Clin Exp Rheumatol; 1996; 14(2):171-6. PubMed ID: 8737723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. F-18 FDG uptake of bone marrow on PET/CT scan: it's correlation with CD38/CD138 expressing myeloma cells in bone marrow of patients with multiple myeloma.
    Ak I; Gulbas Z
    Ann Hematol; 2011 Jan; 90(1):81-7. PubMed ID: 20690019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression to Symptomatic Multiple Myeloma Predicted by Texture Analysis-Derived Parameters in Patients Without Focal Disease at
    Ripani D; Caldarella C; Za T; Rossi E; De Stefano V; Giordano A
    Clin Lymphoma Myeloma Leuk; 2021 Aug; 21(8):536-544. PubMed ID: 33985932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.